Stock Events

Stock Events

Travere Therapeutics 

$65.28
39
-$1.26-1.89% 20:00 Today
-$0.52-0.8%21:02After hours

Statistics

Day High
67.11
Day Low
65.04
52W High
68.03
52W Low
20.84
Volume
1,050,500
Avg. Volume
1,754,460
Mkt Cap
6.15B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.73
-0.39
-0.06
0.28
Expected EPS
0.024076
Actual EPS
N/A

Financials

-5.21%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
490.73MRevenue
-25.55MNet Income

Analyst Ratings

68.44Average Price Target
The highest estimate is 78.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TVTX. It's not an investment recommendation.
Amazon
9
AMZN
NVIDIA
9
NVDA
AMD
8
AMD
Meta Platforms
8
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, competing in the rare disease space similar to Travere.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops enzyme replacement therapies for rare genetic disorders, overlapping with Travere's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a global healthcare company with products in diabetes and rare blood disorders, areas that may overlap with Travere's interests.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio including treatments for rare diseases, competing with Travere in the specialty and rare disease market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for rare diseases, making it a competitor in the same market as Travere.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals develops medications for rare diseases among other conditions, competing with Travere in the biopharmaceutical space.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, rare diseases, and other areas, competing with Travere in the development of treatments for rare conditions.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics for rare diseases, directly competing with Travere's focus.

About

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Show more...
CEO
Eric Dube
Employees
497
Country
United States
ISIN
US89422G1076

Listings

XNAS
US
TVTX
BOATS
BOATS
TVTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Travere Therapeutics stock price today?▼
The current price of TVTX is $65.28 USD — it has decreased by -1.89% in the past 24 hours. Watch Travere Therapeutics stock price performance more closely on the chart.
What is Travere Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Travere Therapeutics stocks are traded under the ticker TVTX.
Is Travere Therapeutics stock price growing?▼
TVTX stock has fallen by -0.59% compared to the previous week, the month change is a +16.53% rise, over the last year Travere Therapeutics has showed a +208.38% increase.
What is Travere Therapeutics market cap?▼
Today Travere Therapeutics has the market capitalization of 6.15B
When is the next Travere Therapeutics earnings date?▼
Travere Therapeutics is going to release the next earnings report on October 22, 2026.
What were Travere Therapeutics earnings last quarter?▼
TVTX earnings for the last quarter are -0.37 USD per share, whereas the estimation was -0.13 USD resulting in a -174.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Travere Therapeutics revenue for the last year?▼
Travere Therapeutics revenue for the last year amounts to 490.73M USD.
What is Travere Therapeutics net income for the last year?▼
TVTX net income for the last year is -25.55M USD.
How many employees does Travere Therapeutics have?▼
As of September 04, 2026, the company has 497 employees.
In which sector is Travere Therapeutics located?▼
Travere Therapeutics operates in the Health & Wellness sector.
When did Travere Therapeutics complete a stock split?▼
Travere Therapeutics has not had any recent stock splits.
Where is Travere Therapeutics headquartered?▼
Travere Therapeutics is headquartered in SAN DIEGO, United States.